Navigation Links
House Passes Historic Bill to Protect Kids from Tobacco; Senators Bennett & Hatch Should Cosponsor Legislation
Date:7/30/2008

SALT LAKE CITY, July 30 /PRNewswire-USNewswire/ -- The U.S. House of Representatives took a historic step today by passing legislation that would grant the U.S. Food and Drug Administration (FDA) authority over tobacco products, including the authority to crack down on tobacco marketing and sales to kids. The bill passed with an overwhelming majority and broad, bipartisan support. The bill now goes to the U.S. Senate for consideration and Utah public health organizations called on Senator Robert Bennett (R-UT) and Senator Orrin Hatch (R-UT) to protect America's kids from tobacco addiction and support the bill.

"Senator Bennett and Senator Hatch have critical roles to play in ensuring that strong FDA tobacco regulation is enacted into law," said Dr. Susan Morelli, Chair of the American Heart Association. "The tobacco industry spends almost $60 million a year marketing its products in Utah. We call on Senators Bennett and Hatch to cosponsor the bill that would grant the FDA authority over tobacco. It's time for Senator Bennett and Senator Hatch to stand up for Utah's kids and help pass strong FDA legislation."

Among other things, the legislation would:

-- Crack down on tobacco marketing and sales to kids;

-- Require larger, more effective health warnings on tobacco products;

-- Require tobacco companies to disclose the contents of tobacco products;

-- Grant the FDA authority to require changes in tobacco products, such as removal or reduction of harmful ingredients;

-- Stop tobacco companies from misleading the public about health risks of their products.

Unbelievably, despite all the harm they cause, tobacco products are exempt from basic health regulations that apply to other products, such as food, drugs, and even cosmetics. The tobacco companies continue to take advantage of this lack of regulation to market their deadly and addictive products to our children, deceive consumers about the harm their
'/>"/>

SOURCE Campaign for Tobacco-Free Kids
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Webcast Alert: Kaiser Permanente Residency Program Open House
2. Houston Texans Star Players Ahman Green and Matt Schaub Help Easter Seals, Avondale House and Local Families Tackle Autism
3. Retailers Welcome Senate Passage of Mental Health Parity Bill, Urge House to Adopt Senate Version at Subcommittee Markup
4. CRC Health Group Announces Acquisition of Durhams Structure House, Weight Loss Facility
5. Senate, House Announce Agreement to Renew, Improve Childrens Health Insurance Program Now
6. Statement on House/Senate Agreement on SCHIP Legislation
7. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
8. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
9. House of Representatives Passes Stop AIDS in Prison Act of 2007
10. Green Seal Ramps Up Environmental Standard for Household Cleaners
11. Pelosi Statement on House Vote to Extend Family and Medical Leave for Military Families
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... ORLEANS, Dec. 7 Cell Therapeutics, Inc. ... Ruth Pettengell, M.D. of St. George,s Hospital, University ... American Society of Hematology ("ASH") Annual Meeting updated ... 301) clinical trial of pixantrone (the "PIX 301 ... lymphoma ("NHL") patients who have failed 2 ...
(Date:12/6/2009)... Pharmacyclics, Inc. (Nasdaq: PCYC ) ... study showing safety and clinical activity in patients ... with its HDAC inhibitor PCI-24781 as a single ... 51st ASH Annual Meeting being held in New ... is an oral pan-HDAC inhibitor which is currently ...
(Date:12/6/2009)... in virus , , SUNDAY, Dec. 6 (HealthDay News) -- Early ... in a tiger that lived thousands or millions of years ... took on a bit of a tiger,s genetic material, scientists ... virus to this day. That tiger, in fact, may have ... that ultimately led to its infection of humans. , The ...
(Date:12/6/2009)... Dec. 6, 2009 A new study provides welcome ... as venous thromboembolism (VTE). , The condition is ... year, and occurs when an abnormal clot forms in ... pain and swelling. In some cases, the clot may ... the heart to the lungs, causing a potentially fatal ...
(Date:12/5/2009)... 5 There have been significant scientific advances in ... to gain a better understanding of how certain diseases ... provide patients with the best care. Research presented today ... of Hematology explores optimal induction therapies for managing multiple ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... American Society of Aesthetic Plastic Surgery indicate a ... including injectable treatments like BOTOX® Cosmetic and major ... since collection of the data began in 1997. ... a number of these popular options, and Beverly ...
... 24 World Veterinary Day, April 25, 2009, celebrates ... year,s theme, ,Veterinarians and Livestock Farmers: a ... highlights a discipline of veterinary medicine the AVMA ... W. Ron DeHaven, DVM, MBA, Chief Executive Officer of ...
... Inc. announces the completion of its transformation from a telemedicine device ... , ... North Chelmsford, MA (PRWEB) April 24, 2009 ... to a Telemedicine Encounter Management Systems company. AMD will showcase ...
... how business and medicine can collaborate to solve today,s ... questions regarding the state of collaboration between industry, academia ... how evolving reimbursement practices are changing what it means ... 30, 2009, 3:00 6:45 p.m. , PLACE: , Weill ...
... study finds , , FRIDAY, April 24 (HealthDay News) -- ... disease are taking the recommended combination of medications to ... on 711 people with peripheral artery disease who had ... in 2004. Three years later, 465 of the surviving ...
... the virus is the same that sickened seven people in ... officials took extraordinary steps Friday to try to contain a ... and possibly dozens more, and sickened more than 900 other ... that it could mark the start of a flu pandemic, ...
Other Medicine News:Health News:Beverly Hills Cosmetic Plastic Surgeon Andrew T. Cohen, MD Helping New Moms Restore their Bodies with a Mommy Makeover 2Health News:Beverly Hills Cosmetic Plastic Surgeon Andrew T. Cohen, MD Helping New Moms Restore their Bodies with a Mommy Makeover 3Health News:AVMA Celebrates World Veterinary Day 2Health News:AMD Global Telemedicine Inc. to Unveil New Solutions at ATA 2009 Conference in Las Vegas 2Health News:With Peripheral Artery Disease, Med Adherence Is Low 2Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 2Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 3Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 4Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 5
(Date:12/4/2009)... Inc. (NYSE Amex: PIP ), a biodefense company ... today the presentation of new data from the Company,s ... Antigen (rPA) based anthrax vaccine is structurally stable and ... and including 55 degrees C. The data were ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), ... and chemical threats, announced today that the Company ... effectiveness of Valortim® in an inhalation anthrax model ... The data are being presented during an oral ...
(Date:12/4/2009)... 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ... that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated ... Drug Administration seeking approval to market its 8mg ramelteon ... by Takeda Pharmaceutical Company Limited. Watson,s 8mg ramelteon ...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 1Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 2Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 3ONRAD Announces New PACS Application Service Provider Model 51165 1ONRAD Announces New PACS Application Service Provider Model 51165 22 reproductive factors are important predictors of death from ovarian cancer 9184 12 reproductive factors are important predictors of death from ovarian cancer 9184 22 reproductive factors are important predictors of death from ovarian cancer 9184 3
... 04, 2007 /PRNewswire-FirstCall/ --,Genta Incorporated announced the ... trial of its marketed product, Ganite(R) (gallium,nitrate ... patients with relapsed or refractory non-Hodgkin's,lymphoma (NHL). ... meeting of,the American Society of Clinical Oncology ...
... Pertuzumab shows promising results in,advanced breast cancer ... BASEL, Switzerland, June 4, 2007-Early clinical results ... medicine pertuzumab, a HER,dimerisation inhibitor, show substantial ... breast cancer, when,combined with Herceptin. The study ...
Other Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5
The Charlotte Shoulder™ System address arthroscopic, mini-open and open procedures with time saving instrumentation....
Arthroscopic instrument system for instability and SLAP fixation....
Suture Cutter, straight...
... The Mini-Open Rotator Cuff Repair ... by,reducing procedure time, incision size and ... system,augments other rotator cuff repair systems ... of,three sizes of matched cortical gauge ...
Medicine Products: